Clinical Trial Update: A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation [Phase 3]

View source ↗

Summary

A 12-week, multicenter, randomized, double-blind, placebo- and active-controlled Phase 3 trial evaluating indacaterol maleate combined with glycopyrronium bromi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Indacaterol maleate / glycopyrronium bromide

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Status: COMPLETED | Results posted: 2015-07-15